According to Wired, virologist Wei Zhao and colleagues at Melbourne’s Peter Doherty Institute for Infection and Immunity are pioneering a new use for Crispr: fighting influenza. Their approach focuses on the Cas13 enzyme, which targets and cuts RNA, the genetic material of flu viruses. The team is developing a system delivered by nasal spray or injection, using lipid nanoparticles to send molecular instructions into respiratory cells. One molecule, an mRNA, tells cells to produce Cas13, while a guide RNA directs it to the flu virus’s RNA to cut it and stop replication. The goal is both to treat active infections and potentially use the spray preventatively during severe flu seasons. Infectious diseases physician Sharon Lewin is leading the project, which was initially explored as a novel Covid antiviral.
Crispr’s New Target
Here’s the thing: we mostly think of Crispr in terms of fixing broken human genes, like in those recently approved therapies for sickle cell disease. It’s a permanent fix for inherited conditions. But targeting a fast-mutating, external invader like the flu? That’s a whole different ballgame. The clever pivot to Cas13 is key because flu is an RNA virus. Cas9 edits DNA, which is stable. Cas13 goes after the more transient RNA, which is perfect for a virus that’s constantly changing. It’s a bit like using a scalpel instead of a sledgehammer—you’re aiming to disrupt the virus’s replication manual without touching the host cell’s permanent library.
The Delivery Challenge
So the science is sound in theory. But the real hurdle, as always in biotech, is delivery. Getting lipid nanoparticles with their mRNA payload into the right cells in the respiratory tract is the make-or-break step. We saw this technology explode with Covid vaccines, but a therapeutic or prophylactic spray is a different application. The idea of “arming” your airway cells like soldiers, as Zhao describes, is powerful. Imagine a bad flu season hits, and instead of just crossing your fingers after a shot, you get a spray that preps your frontline defenses at the genetic level. That’s the vision. But can they make it work reliably and safely outside the lab? That’s the billion-dollar question.
Broader Implications and Hurdles
This isn’t happening in a vacuum. The research builds on earlier work exploring Crispr-Cas13 as an antiviral platform. If successful, it could reshape our entire approach to respiratory viruses. Think beyond flu to RSV, common cold coronaviruses, maybe even the next pandemic threat. But let’s not get ahead of ourselves. The regulatory path for a gene-editing-based antiviral is uncharted. The FDA is comfortable with Crispr for single-gene diseases, but a short-acting, RNA-targeting therapeutic for a common illness? That’s new territory. There are also cost and manufacturing questions. Would this be a boutique, expensive treatment, or could it be scaled to be a public health tool? The team has a long road from the symposium stage to the pharmacy shelf, but the concept is undeniably compelling. It shows how versatile the Crispr toolkit is becoming, moving from rare disease cures to potential mass-market infectious disease controls. The scientific foundation is there, as seen in prior studies on Cas13 systems, but turning it into a product is the next epic challenge.
